Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer-Testis Antigen (CTA) and Hepatocellular Carcinoma (HCC) Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RBMY1E drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RBMY1E Recombinant Protein (Full-Length / RNA-Binding Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View RBMY1E Products |
| Gene Delivery | RBMY1E Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and phenotypic assays. |
View RBMY1E Products |
| Benchmark Ab | Anti-RBMY1E Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and IP assays. |
View RBMY1E Products |
| Validator | RBMY1E siRNA Set For target knockdown and functional specificity verification. |
View RBMY1E Products |
| Related Target A | RBMY1A1 Highly homologous family member; essential for specificity and off-target counter-screening. |
View RBMY1A1 Products |
| Related Target B | GPC3 Co-expressed oncofetal antigen in hepatocellular carcinoma; key partner for combination or bispecific strategies. |
View GPC3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High Homology Off-Target Risks (RBMY Family) | Sequence-verified RBMY1E and RBMY1A1 proteins for precise selectivity assays. |
| Intracellular Target Access & Validation | High-titer Lentiviral particles for stable overexpression in HCC cell lines. |
| Lack of Controls | Sequence-derived benchmark recombinant antibodies included. |
| False Positives in Phenotypic Screening | Validated siRNA sets included for target-specific knockdown verification. |
Live RBMY1E R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of RBMY1E (RNA Binding Motif Protein Y-Linked 1 Family Member E) is emerging as a high-potential frontier in male-biased malignancies, particularly hepatocellular carcinoma (HCC). As a classic Cancer-Testis Antigen (CTA), RBMY1E exhibits highly restricted normal tissue expression (limited to the testes) but is aberrantly reactivated in tumor tissues, where it drives RNA splicing alterations, cell proliferation, and resistance to apoptosis.
The race for RBMY1E therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to intracellular targeting modalities such as TCR-like antibodies (targeting MHC-presented RBMY1E peptides), mRNA-based cancer vaccines, and small-molecule RNA-binding inhibitors. As first-generation immunotherapies reach clinical evaluation, the next wave of R&D is targeting the specific protein-protein and protein-RNA interactions of RBMY1E to selectively disrupt oncogenic splicing networks.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T / TCR-like Ab | Biotech Startups, Academic Institutes | Hepatocellular Carcinoma (HCC), Liver Cancer | MHC-Peptide Complex Validation (Need ultra-pure recombinant protein) |
| mRNA Vaccine | Oncology Vaccine Developers | Solid Tumors, Testicular Cancer | In vitro translation and antigen presentation assays (Need sequence-verified ORF) |
| Small Molecule Inhibitor | Splicing-focused Pharma | Refractory HCC | RNA-binding inhibition assays (Need biologically active RNA-binding domain constructs) |